[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 337
Citations 0
Viewpoint
May 2016

Institutional Conflict of Interest and the Translational Pathway

Author Affiliations
  • 1Duke University School of Medicine, Durham, North Carolina
JAMA Ophthalmol. 2016;134(5):483-484. doi:10.1001/jamaophthalmol.2016.0459

This is an exciting era for translational research, with novel therapeutic and diagnostic approaches for a wide spectrum of diseases, including diseases of the eye. Translational research, the conversion of basic science discoveries into clinical applications, inevitably includes issues regarding the commercialization process. Since the Bayh-Dole Act of 1980, the line of demarcation between the domains of the nonprofit academic institution and the commercial world has become increasingly fuzzy. A recent case example provides an illustration of this blurring and the potential effects of institutional conflict of interest.

First Page Preview View Large
First page PDF preview
First page PDF preview
×